Philip Riches (Affiliate)

Improving the care and understanding of gout, and exploring the pathogenesis of osteoporosis

Research in a Nutshell

Dr Riches is developing an innovative supported self-monitoring approach to gout which has been shown to improve patient outcomes.

He has described the syndrome of osteoporosis caused by osteoprotegerin antibodies published in the New England Journal of Medicine, and collaborated locally and internationally to explore the genetic influences on disease pathogenesis and treatment response in both gout and osteoporosis.

For this work he has received clinical case and new investigator awards from the European Calcified Tissue Society (ECTS), an Innovation award from the British Society of Rheumatology and the Amgen ECTS Bone Biology Fellowship as well as the Doris Hillier award from the British Medical Association Foundation for medical research. Dr Philip Riches is also the Rheumatology module lead for Edinburgh Medical School.

Click here to learn more about GoutSMART

Contact

priches@staffmail.ed.ac.uk

Collaborations

• Professor Tony Merriman, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, United States
• Dr Amrey Krause, Edinburgh Parallel Computing Centre, University of Edinburgh

Partners and Funders

Current research grants

• BMA Medical Foundation £50,857 Gout SMARTER (Gout Self-Monitoring to Achieve urate Target and Evaluate Remission), P Riches (PI), September 2020 for 3 years.
• NHS Rheumatology Endowment Fund £4,477 Supporting gout self-management – Service evaluation, P Riches (PI), May 2023 for 24 months.

Previous Research Grants

• NHS Rheumatology Endowment Fund, £27,182 Gout SMART (Gout Self-Monitoring Aiming to Reach Target urate) feasibility trial, P Riches (PI), May 2019 for 24 months.
• NHS Rheumatology Endowment Fund, £27,510 Gout SMART App development, P Riches (PI), May 2018 for 12 months.
• Coeliac UK/CORE, £80,756 Research Grant: Osteoporosis in coeliac disease associated with novel autoantibodies, P Riches (PI), J Satsangi, SH Ralston, January 2013 for 3 years.
• National Osteoporosis Society, £104,740 Research grant: Osteoprotegerin antibodies in the pathogenesis and management of severe osteoporosis, P Riches (PI), WD Fraser, SH Ralston, January 2012 for 3 years.
• Chief Scientist Office, Scotland, £210,150 Research Grant: Predicting therapeutic response to teriparatide therapy in osteoporosis by genetic profiling, N Alonso (PI), P Riches, SH Ralston, August 2015 for 18 months.
• Institute of Genetics and Molecular Medicine, Edinburgh UK, £90,000 Research Fellowship: P Riches, SH Ralston (Sponsor), September 2007 for 2 years.
• Royal College of Surgeons, Edinburgh UK, £120,000 Lorna Smith Fellowship: Role of the SLC2A9 gene in the pathogenesis of 3 hyperuricaemia and gout, P Riches (PI), SH Ralston (Co-Investigator), April 2009 for 2 years.
• European Calcified Tissue Symposium (ECTS)/Amgen, €100,000 Bone Biology Fellowship: P Riches, SH Ralston (Sponsor), March 2010 for 3 years.
• Chief Scientist Office, Scotland, £280,302 Research Grant: Do neutralising antibodies to osteoprotegerin explain the association between cardiovascular disease and osteoporosis? P Riches (PI), J Wilson, SH Ralston; September 2010 for 2 years (granted 6 month extension).